PHILADELPHIA, VANCOUVER, British Columbia — November 18, 2025 — Leads & Copy —
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) will present three clinical and one preclinical posters at the 2025 San Antonio Breast Cancer Symposium (SABCS®) from December 9-12, 2025, in San Antonio, Texas.
Two of the poster presentations are considered potentially high impact late-breaking clinical posters, according to BriaCell President & CEO William V. Williams, MD. Williams said the company will present significant data to breast cancer scientific experts and cancer specialists, advancing their therapies to develop better clinical outcomes for cancer patients.
Presentation details:
Late-Breaking Abstract Number: 3688
Presentation Number: PS1-13-22
Presentation Title: Impact of Prior Therapy, Genotype Matching, and Biomarkers in the Bria-ABC Phase 3 Trial
Poster Presentation Date/Time: Wednesday, December 10, 2025, 12:30 PM – 2:00 PM
Late-Breaking Abstract Number: 3713
Presentation Number: PS1-13-23
Presentation Title: Survival Results of Phase II Bria-IMT Allogenic Whole Cell-Based Cancer Vaccine
Poster Presentation Date/Time: Wednesday, December 10, 2025, 12:30 PM – 2:00 PM
Abstract Number: 1614
Presentation Number: PS2-09-03
Presentation Title: Th1-biased cytokine signatures as biomarkers of clinical benefit following SV-BR-1-GM cancer vaccination in breast cancer.
Poster Presentation Date/Time: Wednesday, December 10, 2025, 5:00 PM – 6:30 PM
Copies of the posters will be available after the presentation at https://briacell.com/scientific-publications/.
BriaCell is a clinical-stage biotechnology company focused on developing immunotherapies for cancer care.
William V. Williams, MD, President & CEO
1-888-485-6340
info@briacell.com
Investor Relations:
investors@briacell.com
Source: BriaCell Therapeutics Corp.
